Peripheral Blood Clonotypic Mass Spectrometry-Based MRD Stratification Identifies Patients at Increased Risk of Progression After Quadruplet Therapy in NDMM
Monitoring measurable residual disease (MRD) in newly diagnosed multiple myeloma (NDMM) remains challenging due to the need for repeated bone marrow sampling. The study summarized in this poster evaluates M-inSight®, a minimally invasive, blood-based mass spectrometry assay, as a tool for MRD assessment and risk stratification in patients who achieved complete response following quadruplet therapy.
M-inSight® identified patients at significantly higher risk of disease progression and provided prognostic information complementary to bone marrow next-generation sequencing (NGS) MRD testing. Patients who were MRD-negative by both peripheral blood M-inSight® and bone marrow NGS experienced the most favorable outcomes, supporting the value of combining both approaches. These findings highlight the potential of M-inSight® as a patient-friendly solution for longitudinal MRD monitoring and improved risk stratification while reducing reliance on invasive bone marrow assessments.